Accepted Manuscripts
January 19, 2021
- Experimental TherapeuticsIn vivo targeting of E. coli with vancomycin-arginine
- Experimental TherapeuticsDeletion of PknG abates reactivation of latent Mycobacterium tuberculosis in mice
- Experimental TherapeuticsThe antibiotic negamycin crosses the bacterial cytoplasmic membrane by multiple routes
- Experimental TherapeuticsBoromycin has potent anti-Toxoplasma and anti-Cryptosporidium activity
- Mechanisms of ResistanceCarbapenem use is driving the evolution of IMiPenemase (IMP)-1 variants
Pages
DISCLAIMER: These manuscripts are provided "as is" without warranty of any kind, either expressly for a particular purpose, or non-infringement. Changes will be made to these manuscripts before publication. Review and/or use or reliance on these materials is at the discretion and risk of the reader/user. In no event shall the American Society for Microbiology be liable for damages of any kind arising from these materials; references to products or publications do not imply endorsement of those products or publications.
Accepted Manuscripts are PDF versions of manuscripts that have been peer reviewed and accepted but not yet copyedited. The manuscripts are published online as soon as possible after acceptance, on a weekly basis, before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by the authors at the modification stage) and do not reflect ASM editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the accepted manuscripts and the final, typeset articles. The manuscripts remain listed on the Accepted Manuscripts page until the final, typeset articles are posted. Supplemental material intended, and accepted, for publication is not posted until publication of the final, typeset articles.